Brigitte Dréno, MD, PhD of the University Hospital of Nantes, Nantes, France discusses vaccinations for melanoma and the decrease in the number of clinical trials being carried out. She explains the decrease in trials and that there has been a move to adjuvant therapy. Unfortunately it was found that the last trial (called DERMA, NCT00796445) that was carried out with melanoma-associated antigen 3 (MAGE-A3), was also negative. Prof. Dréno thinks that the future might be virus oncolytic immunotherapy, involving a modified herpes virus. Further, we need to have a better knowledge of the different mechanisms to hope to progress in the field of peptide vaccination. Recorded at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria.